Champions Oncology Reports Q1 Fiscal 2027 Earnings with Revenue Growth and Improved Margins
Champions Oncology (NASDAQ:CSBR) reported first-quarter fiscal year 2027 results showing a 9% revenue increase to $15.2 million, along with improved profitability metrics including adjusted EBITDA of $671,000—up from $59,000 in the prior-year quarter and marking its fifth consecutive positive result. The company's translational oncology services segment saw a 51% margin improvement to 43%, driven by lower third-party radiolabeling costs and operating leverage. Data licensing revenue reached $893,000 for the first quarter alone, surpassing the full fiscal year 2026 total. CEO Rob Brainin highlighted that this growth reflects a broader customer base and increased demand from drug developers using AI in research decisions. The company ended the quarter with $4.4 million in cash and no debt while continuing to explore potential funding or licensing opportunities for its Corellia platform. Despite reporting a GAAP net loss of approximately $426,000—improved compared to last year’s operational losses—the management remains optimistic about fiscal 2027 as it aims to demonstrate the returns on prior investments in both revenue and margin expansion.
Tickers: $CSBR
Topics: adjusted_ebitda data_licensing revenue_growth services_margins